Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

BACKGROUND: Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway, the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ERα)...

Full description

Saved in:
Bibliographic Details
Published in:BMC Cancer
Main Authors: Becker, Marc A., Hou, Xiaonan, Tienchaianada, Piyawan, Haines, Brian B., Harrington, Sean C., Weroha, S. John, Sathyanarayanan, Sriram, Haluska, Paul
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5073873/
https://ncbi.nlm.nih.gov/pubmed/27765027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2847-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items